Disease patterns and specific trajectories of anti-MDA5-related disease: a multicentre retrospective study of 70 adult patients.

anti-MDA5 dermatomyositis malignancy prognosis rapidly progressive interstitial lung disease thromboembolic events

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 11 10 2023
accepted: 15 12 2023
medline: 23 1 2024
pubmed: 23 1 2024
entrez: 23 1 2024
Statut: epublish

Résumé

This study aimed to provide an updated analysis of the different prognostic trajectories of patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibodies. Among a cohort of 70 patients, baseline characteristics and phenotypes, treatments and outcomes were analyzed. A Cox proportional hazards model was used to identify factors associated with poor outcomes, i.e., death or progressive disease at the last follow-up. Among the 70 patients, 45 were women, and 54 were Caucasian. A dermatologic involvement was observed in 58 (83%) patients, including 40 with MDA5 vasculopathy-related skin lesions. Muscular involvement was observed in 39 (56%) patients. Interstitial lung disease (ILD) was observed at baseline in 52 (74%) patients, including 23 (44%) who developed rapidly progressive (RP) ILD. Seven (10%) patients showed thromboembolic complications within the first weeks of diagnosis, and eight (11%) other patients developed a malignancy (4 before the diagnosis of anti-MDA5 disease). Poor outcomes were observed in 28 (40%) patients, including 13 (19%) deaths. Among the 23 patients with RP-ILD, 19 (79%) showed poor outcomes, including 12 (63%) who died. In multivariate analyses, RP-ILD (hazard ratio (HR), 95% CI: 8.24 [3.21-22], p<0.0001), the occurrence of thromboembolic events (HR: 5.22 [1.61-14.77], p=0.008) and the presence of any malignancy (HR: 19.73 [6.67-60], p<0.0001) were the three factors independently associated with poor outcomes. This new independent cohort confirms the presence of different clinical phenotypes of anti-MDA5 diseases at baseline and the poor prognosis associated with RP-ILD. Thromboembolic events and malignancies were also identified as prognostic factors.

Identifiants

pubmed: 38259447
doi: 10.3389/fimmu.2023.1319957
pmc: PMC10800864
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1319957

Informations de copyright

Copyright © 2024 de Boysson, Cuchet, Cassius, Cuchet, Agard, Audemard-Verger, Marchand-Adam, Cohen-Sors, Gallay, Graveleau, Lesort, Ly, Meyer, Monseau, Néel, Bonnotte, Pérard, Schleinitz, Mariotte, Le Mauff, Bourdenet, Masmoudi, Deshayes, Dumont, Dompmartin, Kottler and Aouba.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer CB declared a shared parent affiliation with the author CC to the handling editor at the time of review.

Auteurs

Hubert de Boysson (H)

Department of Internal Medicine, Caen University Hospital, Caen, France.

Marie Cuchet (M)

Department of Dermatology, Caen University Hospital, Caen, France.

Charles Cassius (C)

Department of Dermatology, France Saint Louis Hospital, (AP-HP), Paris, France.

Pierre Cuchet (P)

Department of Pneumology, Caen University Hospital, Caen, France.

Christian Agard (C)

Nantes Université, Centre Hospitalier et Universitaire (CHU) Nantes, Service de Médecine Interne, Nantes, France.

Alexandra Audemard-Verger (A)

Department of Internal Medicine, Tours University Hospital, Tours, France.

Sylvain Marchand-Adam (S)

Department of Pneumology, Tours University Hospital, Tours, France.

Raphaëlla Cohen-Sors (R)

Department of Dermatology, Amiens University Hospital, Amiens, France.

Laure Gallay (L)

Service de Médecine Interne et Immunologie Clinique, Hôpital Édouard Herriot, Hospices Civils de Lyon, Lyon, France.

Julie Graveleau (J)

Department of Internal Medicine, Saint-Nazaire Hospital, Saint-Nazaire, France.

Cécile Lesort (C)

Department of Dermatology, Edouard Herriot Hospital, Hospices civiles de Lyon (HCL), Lyon, France.

Kim Ly (K)

Department of Internal Medicine, Limoges University Hospital, Limoges, France.

Alain Meyer (A)

Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France.

Grégoire Monseau (G)

Department of Intensive Medicine, Poitiers University Hospital Center, Poitiers, France.

Antoine Néel (A)

Nantes Université, Centre Hospitalier et Universitaire (CHU) Nantes, Service de Médecine Interne, Nantes, France.

Bernard Bonnotte (B)

Department of Internal Medicine, Dijon University Hospital, Dijon, France.

Laurent Pérard (L)

Department of Internal Medicine, Saint Joseph Saint Luc Hospital, Lyon, France.

Nicolas Schleinitz (N)

Department of Internal Medicine, La Timone University Hospital, Assistance Publique - Hopitaux de Marseille (AP-HM), Marseille, France.

Delphine Mariotte (D)

Department of Immunology, Caen University Hospital, Caen, France.

Brigitte Le Mauff (B)

Department of Immunology, Caen University Hospital, Caen, France.

Gwladys Bourdenet (G)

Department of Immunology, Amiens University Hospital, Amiens, France.
HEMATIM - EA4666, Jules Verne University of Picardie, Amiens, France.

Wafa Masmoudi (W)

Department of Dermatology, Rouen University Hospital, Rouen, France.

Samuel Deshayes (S)

Department of Internal Medicine, Caen University Hospital, Caen, France.

Anaël Dumont (A)

Department of Internal Medicine, Caen University Hospital, Caen, France.

Anne Dompmartin (A)

Department of Dermatology, Caen University Hospital, Caen, France.

Diane Kottler (D)

Department of Dermatology, Caen University Hospital, Caen, France.

Achille Aouba (A)

Department of Internal Medicine, Caen University Hospital, Caen, France.

Classifications MeSH